GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » LENSAR Inc (NAS:LNSR) » Definitions » EV-to-EBIT

LENSAR (LENSAR) EV-to-EBIT : -1.13 (As of May. 01, 2024)


View and export this data going back to 2020. Start your Free Trial

What is LENSAR EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, LENSAR's Enterprise Value is $13.80 Mil. LENSAR's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-12.23 Mil. Therefore, LENSAR's EV-to-EBIT for today is -1.13.

The historical rank and industry rank for LENSAR's EV-to-EBIT or its related term are showing as below:

LNSR' s EV-to-EBIT Range Over the Past 10 Years
Min: -3.37   Med: -1.64   Max: -0.29
Current: -1.13

During the past 5 years, the highest EV-to-EBIT of LENSAR was -0.29. The lowest was -3.37. And the median was -1.64.

LNSR's EV-to-EBIT is ranked worse than
100% of 464 companies
in the Medical Devices & Instruments industry
Industry Median: 20.05 vs LNSR: -1.13

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. LENSAR's Enterprise Value for the quarter that ended in Dec. 2023 was $18.00 Mil. LENSAR's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-12.23 Mil. LENSAR's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -67.93%.


LENSAR EV-to-EBIT Historical Data

The historical data trend for LENSAR's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LENSAR EV-to-EBIT Chart

LENSAR Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
- -2.30 -1.91 -1.04 -1.47

LENSAR Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.04 -1.25 -1.77 -1.03 -1.47

Competitive Comparison of LENSAR's EV-to-EBIT

For the Medical Devices subindustry, LENSAR's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


LENSAR's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, LENSAR's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where LENSAR's EV-to-EBIT falls into.



LENSAR EV-to-EBIT Calculation

LENSAR's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=13.798/-12.229
=-1.13

LENSAR's current Enterprise Value is $13.80 Mil.
LENSAR's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-12.23 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


LENSAR  (NAS:LNSR) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

LENSAR's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=-12.229/18.00277
=-67.93 %

LENSAR's Enterprise Value for the quarter that ended in Dec. 2023 was $18.00 Mil.
LENSAR's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-12.23 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


LENSAR EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of LENSAR's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


LENSAR (LENSAR) Business Description

Traded in Other Exchanges
N/A
Address
2800 Discovery Drive, Orlando, FL, USA, 32826
LENSAR Inc is a commercial-stage medical device company focused on designing, developing and marketing a femtosecond laser system for the treatment of cataracts. The company Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency and reproducibility by providing imaging, simplified procedure planning, efficient design and precision. Its product portfolio consists of the LENSAR Laser System with Streamline IV and IntelliAxis and its associated consumable components. The consumable portion of the system consists of a disposable patient interface device, or PID, kit and a procedure license. Each procedure on each system requires the use of a PID kit.
Executives
Gary M Winer director C/O LENSAR, INC., 2800 DISCOVERY DRIVE, ORLANDO FL 32826
Aimee S Weisner director ONE EDWARDS WAY, IRVINE CA 92614
Nr-gri Partners Gp, Llc 10 percent owner 867 BOYLSTON STREET, 5TH FLOOR, #1361, BOSTON MA 02116
Nr-gri Partners, Lp 10 percent owner 867 BOYLSTON STREET, 5TH FLOOR, #1361, BOSTON MA 02116
Todd B Hammer director, 10 percent owner NORTH RUN CAPITAL PARTNERS, 867 BOYLSTON ST., 5TH FLOOR, #1361, BOSTON MA 02116
Thomas B Ellis director, 10 percent owner 867 BOYLSTON STREET, 5TH FLOOR, #1361, BOSTON MA 02116
North Run Advisors, Llc 10 percent owner 62 WALNUT STREET, WELLESLEY MA 02481
North Run Capital, Lp 10 percent owner 867 BOYLSTON STREET, 5TH FLOOR, #1361, BOSTON MA 02116
Staab Thomas R Ii officer: Chief Financial Officer C/O INSPIRE PHARMACEUTICALS, INC., 4222 EMPEROR BLVD., SUITE 200, DURHAM NC 27703
Kendra Wong officer: Principal Accounting Officer C/O LENSAR, INC., 2800 DISCOVERY DRIVE, SUITE 100, ORLANDO FL 32826
Elizabeth G. O'farrell director 932 SOUTHWOOD BLVD., INCLINE VILLAGE NV 89451
Alan B. Connaughton officer: Chief Operating Officer C/O LENSAR, INC., 2800 DISCOVERY DRIVE, ORLANDO FL 32826
Nicholas T Curtis director, officer: Chief Executive Officer C/O STAAR SURGICAL CO, 1911 WALKER AVE, MONROVIA CA 91016
Pdl Biopharma, Inc. 10 percent owner 59 DAMONTE RANCH PARKWAY, SUITE B-375, RENO NV 89521
Lindstrom Richard L Md director 2811 WESTWOOD PL, WAYZATA MN 55391